

Practical Flow Cytometry in Haematology Diagnosis

Mike Leach, Mark Drummond and Allyson Doig



 WILEY-BLACKWELL

Practical Flow Cytometry in Haematology Diagnosis

Mike Leach FRCP, FRCPath

Consultant Haematologist and Honorary Senior Lecturer
Haematology Laboratories and West of Scotland Cancer Centre
Gartnavel General Hospital
Glasgow, UK

Mark Drummond PhD, FRCPath

Consultant Haematologist and Honorary Senior Lecturer
Haematology Laboratories and West of Scotland Cancer Centre
Gartnavel General Hospital
Glasgow, UK



Allyson Doig MSc, FIBMS

Haemato-Oncology Laboratory Manager
Haematology Laboratories
Gartnavel General Hospital
Glasgow, UK

 **WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

This edition first published 2013, © 2013 by John Wiley & Sons, Ltd

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical and Medical business with Blackwell Publishing.

Registered Office

John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Offices

9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Leach, Richard M., MD.

Practical flow cytometry in haematology diagnosis / Mike Leach, Mark Drummond, Allyson Doig.

p. : cm.

Includes bibliographical references and index.

Summary: "This book acts as a clinical manual for the diagnostician who cannot turn to reference books when the morphology or immunophenotype are atypical. This volume presents a logical practical approach to the diagnosis of blood disorders, both neoplastic and reactive, and other diagnostic applications of flow cytometry in non-neoplastic haematology diagnosis. Illustrations are provided throughout with worked examples"—Provided by publisher.

ISBN 978-0-470-67120-7 (hardback : alk. paper) – ISBN 978-1-118-48795-2 (Mobi) – ISBN 978-1-118-48796-9 (obook) – ISBN 978-1-118-48797-6 (epub) – ISBN 978-1-118-48799-0 (ePDF/ebook)

I. Drummond, Mark, PhD. II. Doig, Allyson. III. Title.

[DNLM: 1. Hematologic Diseases–diagnosis. 2. Hematologic Neoplasms–diagnosis.

3. Flow Cytometry–methods. 4. Hematology–methods. WH 120]

616.1'5075–dc23

2012029836

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover design by Steve Thompson

Set in 9/12pt Minion by SPi Publisher Services, Pondicherry, India

Printed and bound in Singapore by Markono Print Media Pte Ltd

Practical Flow Cytometry in Haematology Diagnosis

Practical Flow Cytometry in Haematological Diagnosis

Mike Leach FRCP, FRCPath

Consultant Haematologist and Specialist Haematologist
Immunology Unit, Glasgow and HMV at Gartnavel General Hospital
Glasgow General Hospital
Glasgow, UK

Mark Drummond PhD, FRCPath


Consultant Haematologist and Director, Immunology Unit
Immunology Laboratory, Glasgow General Hospital
Glasgow General Hospital
Glasgow, UK

Allyson Daig MSc, PhD

Research Scientist/Immunology Research
Immunology Laboratory
Glasgow General Hospital
Glasgow, UK

WILEY-BLACKWELL

John Wiley & Sons Ltd, 9600 Garsington Road



9 781118 000000

This book is dedicated to Dr Norman Lucie, pioneer of flow cytometry
in Glasgow.

Preface

The accurate diagnosis of haematologic malignancies is a complex and challenging task. It routinely involves morphologic, molecular, cytogenetic and flow cytometric expertise; how these results are integrated, interpreted and reported will ultimately determine what treatment protocol will be followed. Flow cytometry is central in this diagnostic pathway.

When the authors began to develop their interest in flow cytometry there were few texts available to assist in the day-to-day interpretation of results from clinical samples. The laboratory texts in most frequent use were technically orientated to assist the cytometrist in providing quality data for subsequent reporting. Excellent morphologic and haematopathology texts were available, but a readable, clinically orientated flow cytometry text was notably absent. Things have certainly changed, with a plethora of textbooks describing the application of flow cytometry in the routine diagnostic laboratory. These have taken a varied approach, with case-based, pattern-based and traditional pathological entity-based approaches having appeared over the years. However the authors consider something still to be missing, namely the textbook they would have wanted to pick up 15 years ago as enthusiastic but inexperienced flow cytometrists who wanted to better learn how to interpret the data to inform their haematology practice. Two of the authors of this book are practicing haematologists who between them routinely diagnose and treat all the malignancies described herein. There is therefore a clinical emphasis throughout, as to how flow cytometry results should be interpreted and applied to optimize patient care. In the real world samples arrive from a range of body fluids, from both malignant and benign conditions and are of variable quality. We have endeavored to reflect this. This book is therefore not a technical manual, but instead it is

aimed at those who instigate, perform, interpret or act upon flow cytometry on patient material. This might include clinical scientists, pathologists, haematologists and research laboratory staff. It has therefore been written to encompass the varied background and knowledge of these individuals. Although it has been written to be read from cover to cover it will be a useful laboratory reference text, and we hope of use to both novice and expert alike.

The approach the authors have taken is to start with the basics in each chapter and 'work up'. We have deliberately kept the number of data plots and histograms on display to a useful minimum to allow the text to flow, and inserted carefully chosen real-life cases in each chapter where relevant. High quality morphological images captured especially for this book are used throughout to illustrate these cases. While there is a necessary emphasis on haematological malignancy, flow cytometry of normal populations is not neglected and somewhat uniquely we emphasize the abnormalities that may be encountered as reactive phenomenon, as well as the challenges encountered across a variety of body fluids. That said, this textbook has a traditional structure in terms of the pathological entities described. This is for the simple reason that in most clinical situations, be it based on clinical features, blood indices or initial morphology the investigating clinician or pathologist will have some idea as to what type of disorder they are likely dealing with from the outset. We hope that the readers of this text will enjoy it as much as we enjoyed writing it.

Mike Leach
Mark Drummond
Allyson Doig
Glasgow

Acknowledgements

The authors wish to thank Linda Knotts, Chief Biomedical Scientist at Haematology Laboratories, Yorkhill Hospital, Glasgow for her contribution to Chapter 9, in particular

the role of minimal residual disease assessment in acute lymphoblastic leukaemia.

John G. Macdonald
John G. Macdonald
John G. Macdonald
John G. Macdonald
John G. Macdonald

Contents

Preface, vii

Acknowledgements, viii

1 Introduction, 1

References, 2

2 Principles of Flow Cytometry, 3

Introduction, 3

Sample preparation, 3

The flow cytometer, 4

The fluidic system, 4

The optical system, 5

The electronic system, 9

Data display, 9

Acknowledgements, 18

References, 19

3 Limitations, 20

Introduction, 20

Clinical context issues, 20

Sampling issues, 20

Technical issues, 25

Interpretation issues, 28

Conclusion, 29

References, 29

4 Normal Blood and Bone Marrow Populations, 31

Normal stem and precursor cell populations, 31

References, 41

5 Acute Leukaemia, 43

Introduction, 43

Identification of neoplastic precursor cells, 45

Lineage assignment of acute leukaemia, 52

Acute myeloid leukaemia, 54

Precursor lymphoid neoplasms (acute lymphoblastic leukaemia/lymphoma), 77

Examination of cerebro-spinal fluid and serous effusions, 88

Identification of genetic abnormalities by flow, 92

Conclusion, 93

References, 93

6 Chronic Lymphoid Leukaemias and Exfoliating Lymphoma, 100

Normal peripheral blood lymphoid populations, 100

Identification of clonal lymphoid populations, 101

Identification of clonal B-cell disorders, 101

CD5 positive B-cell lymphoproliferative disorders, 102

CD10 positive B-cell lymphoproliferative disorders, 116

B-cell disorders identified using an extended B-cell panel, 121

Identification of clonal T-cell disorders, 125

CD4 positive T-cell disorders, 128

CD8 positive T-cell disorders, 136

CD4/CD8 positive T-cell disorders, 141

CD4/8 negative disorders, 141

Flow cytometric assessment of serous effusions, 146

Flow cytometric assessment of cerebrospinal fluid, 146

Summary, 149

References, 149

7 Myelodysplastic Syndromes and Myeloproliferative

Neoplasms, 152

Introduction, 152

Myelodysplastic syndromes, 152

Myelodysplastic/myeloproliferative neoplasms, 163

Chronic myeloid leukaemia, 165

The BCR-ABL negative myeloproliferative neoplasms, 166

Mastocytosis, 167

Summary, 170

References, 170

- 8 Disorders of Plasma Cells, 173
Plasma cell disorders, 173
Current diagnostic criteria, 173
Plasma cell morphology, 175
The applications of immunophenotyping
to plasma cell disorders, 178
References, 183
- 9 Minimal Residual Disease, 184
Introduction, 184
Minimal residual disease analysis in the management
of acute lymphoblastic leukaemia, 187
Conclusions, 199
Acknowledgements, 200
References, 200
- 10 Red Cells, Leucocytes and Platelets, 202
Paroxysmal nocturnal haemoglobinuria, 202
Red cell membrane disorders, 208
- 11 Foetal maternal haemorrhage, 211
Lymphocyte subset analysis
and immunodeficiency, 214
Haemopoietic stem cell enumeration, 214
Granulocyte disorders, 215
Platelet disorders, 219
References, 221
- 12 Reactive and Non-neoplastic Phenomena, 225
Peripheral blood, 225
Bone marrow, 231
Pleural and pericardial fluids, 236
Bronchoalveolar lavage specimens, 238
Cerebrospinal fluid, 238
References, 240
- Index, 243

CHAPTER 1

Introduction

The field of Clinical Haematology is a rapidly evolving specialty. The clinical entities encountered in everyday practice have basically not changed, but our understanding of them and the biological and molecular processes that drive them are undoubtedly much better understood. Our classification of these diseases has been continually refined over the decades, with the WHO classification of tumours of haematopoietic and lymphoid tissues now being firmly established as our current working reference manual [1]. The introduction of the WHO classification of haematological malignancy provides a structure for the development of integrated haematopathology laboratories, with its emphasis on definition of disease entities based on clinical, morphological, phenotypic and molecular features.

The real fascination of diagnostic clinical haematology lies in the diversity of the entities that we encounter. The whole spectrum of abnormal haematological parameters triggered by a variety of reactive and neoplastic processes are studied in the diagnostic laboratory. Flow cytometers are no longer a technical novelty confined to a few highly specialized diagnostic institutions. The flow cytometer methodology is well known, cytometers are readily available and whilst its applications are constantly diversifying its contribution to routine diagnosis is widely appreciated. This technology provides objective, rapid, sensitive and accurate measurement of a broad range of cell characteristics.

Accurate diagnosis is clearly of utmost importance in making decisions on patient management. The cognitive pathways to explain the processes of achieving a diagnosis, have in our opinion, however, been somewhat neglected in the haematological literature. There are many excellent texts which describe the clinical, haematological, immunophenotypic, cytogenetic and molecular char-

acteristics of a wide variety of neoplastic disorders. These texts are ideal reference manuals to study once a diagnosis has been achieved. The missing element, however, is a systematic approach to immunophenotypic diagnosis, taking into account all available clinical and laboratory data. In laboratory diagnostics, we are often left with the chore of finding the missing piece to the jigsaw puzzle. This should not be through a process of aimless searching but should be achieved through a logical carefully considered approach. What this publication aims to achieve is to generate a readable text to clearly explain the principles by which these diagnoses can be achieved, how immunophenotypic data can be analysed in clinical context and how meaningful conclusions can be drawn. We focus on clinical flow cytometry analysis of normal and malignant cells, not just in blood and bone marrow, but also cells in extramedullary sites such as effusions and cerebrospinal fluid. Each of these specimens needs to be handled, analysed and interpreted in a specific way. Of utmost importance is the assessment of features of the clinical history, physical examination, biochemical, immunological and radiological findings of a clinical case in relation to the current haematological parameters. We make no apology for this, as we believe this is of ultimate importance and this principle will be encountered repeatedly throughout this text. This approach, as recommended by the National Institute of Clinical Excellence [2], suggests that the diagnosis of leukaemia and lymphoma should take place in a specialist laboratory and in most cases this should be organized on a regional basis with full access to, and interaction with, diagnostic histopathology, cytogenetic and molecular laboratories with expertise in this field.

Flow cytometry analysis, used to determine the nature, origin and behaviour of cells if carefully directed can be a magnificent diagnostic tool and is exquisite in

categorizing cell populations present at low levels through the analysis of cell size, complexity and granularity in relation to the expression of surface, cytoplasmic and nuclear antigens. Many thousands of cells can be so categorized over a short timeframe. It cannot, however, be applied in isolation and flow cytometry, if poorly directed, can lead to erroneous conclusions. For example, identification of the diseased cell population is usually easy in a bone marrow aspirate in a patient presenting with pancytopenia due to acute leukaemia. The disease cells may not be apparent in peripheral blood but are abundant in bone marrow and are identified and categorized using a carefully chosen myeloid panel. In contrast, the disease cells in hairy cell leukaemia may form a minority population in peripheral blood in a second patient with pancytopenia. The bone marrow aspirate is often dry and uninformative. Immunophenotyping using a mature lymphoid panel will provide a diagnosis. Unless the material is carefully scrutinized and the clinical presentation taken into account, then immunophenotyping can be misdirected and the wrong conclusions might be drawn.

We aim to explain from those most basic steps, how to approach clinical flow cytometry analysis of a variety of clinical specimens, to highlight the strengths and pitfalls, and how to safely embark on this fascinating diagnostic process in a variety of clinical circumstances. We aim to cover reactive phenomena, which in our opinion have not been well covered in the world literature. We aim to illustrate to the student that there is clear logic to explain the immunophenotype of any clonal condition and that they should understand this basis and not attempt to remember an immunophenotype as a random set of CD numbers. This latter approach is bound to fail. The former approach will establish a firm understanding and foundation on which to build and will assist in suggesting additional immunophenotypic studies or ancillary investigations in situations where the diagnosis

is not immediately apparent. In addition to the diagnosis of leukaemia and lymphoma we look at flow cytometric applications to response assessment and quantification of minimal residual disease. Finally, we also look at FCM analysis with respect to the diagnosis of red cell, granulocyte and platelet disorders.

This text is written for trainee and practising haematologists, haematopathologists and biomedical scientists with a specific interest. It should assist in preparation for FRCPath UK in Haematology and is intended as a working manual for diagnostic laboratories throughout the world. The chapters are illustrated with morphology images, scatter plots, cytogenetic and molecular data from real clinical cases – often a carefully chosen image will illustrate a principle much more succinctly than a thousand written words.

The authors have done their utmost to ensure the accuracy of data presented in this text. In fact, one of the driving forces in undertaking this exercise was to provide a practical handbook that would assist in the safe and accurate use of flow cytometry as a diagnostic tool. The content is extensively researched and referenced but also relates to personal experience of the authors who interpret flow cytometry on a daily basis in a regional reference centre. We sincerely hope that our readers will find it of interest and of practical value when applied to haematology diagnosis. We cannot, however, accept any responsibility for any error or misinterpretation which might, in any way, arise from its use.

References

- 1 Swerdlow S. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: International Agency for Research on Cancer*. 2008. World Health Organization, Geneva.
- 2 Jack A. Organisation of neoplastic haematopathology services: a UK perspective. *Pathology* 2005, 37(6): 479–92.

Principles of Flow Cytometry

Introduction

Over the years, flow cytometry technology, with its multiple applications, has had a significant impact on our understanding of cell biology, immunology and haemopoietic ontogeny, allowing its application to the diagnostic challenges of clinical medicine.

The basic principle of flow cytometry is inherent in the ability to analyse multiple characteristics of a single cell within a heterogeneous population, in a short period of time [1, 2]. The term heterogeneous is very important. In many clinical scenarios it might be far from clear whether a cellular proliferation is reactive or, indeed, neoplastic. Furthermore, these populations do not exist in isolation but within a milieu of other cell types. The diversity of diseases afflicting the cells of the body compartments is vast. Clinico-pathological correlation is at the very core of accurate diagnosis. Ignore the characteristics of either, at your peril.

Modern flow cytometers have the capability to analyse several thousands of cells per second. Cells in suspension pass through a beam of light (usually a laser beam) in single file; signals generated are related to the size of the cell and the internal complexity or granularity of the cell, enabling the cytometer to identify different cell populations depending on these characteristics. There are a wide range of applications for flow cytometry in a number of different disciplines. However, in haematology it has become an important tool in the identification of haematological disorders from a wide range of diagnostic samples, such as peripheral blood, bone marrow, CSF, pleural effusion, ascitic fluid and lymph node aspirates [1]. For the analysis of solid tissue a cell suspension must first be made.

There are many books and articles available outlining the principles of flow cytometry in great detail [1–7]. This chapter is written with the view of giving a simplified overview of flow cytometry, the gating strategies and data analysis applied in diagnostic flow cytometry applied to haematological disorders. It is aimed at laboratory staff and junior medical staff, and even more senior staff who have not had the privilege to experience clinical flow cytometry in all its diagnostic applications.

Sample preparation

At the outset we begin with a sample, usually of blood or bone marrow. We need to interrogate the cells in the sample as to their nature by determining their surface, cytoplasmic or nuclear immunophenotypic characteristics. As an example (clearly sample management will vary from one institution to another) the following is a simplified version of a sample preparation for flow analysis in our institution.

Direct staining method for surface immunophenotyping of peripheral blood or bone marrow (lyse – no wash method)

- 1 If sample white cell count is normal, sample may be used undiluted. If white cell count is raised, dilute sample in phosphate-buffered saline (PBS) to within normal value. (For example, if WBC twice normal then dilute 1:2.)
- 2 Label FACS tubes with sample ID and antibody combinations according to panel being run.
- 3 Add sample (100 µl) to required number of tubes.

- 4 Add antibody conjugates to sample in volumes as recommended by manufacturer and mix.
- 5 Incubate at room temperature for 20–30 min in the dark.
- 6 Add appropriate volume of ammonium chloride RBC lysing solution and vortex.
- 7 Allow to lyse for 10 min.
- 8 Analyse on flow cytometer.

Surface immunoglobulin staining

- 1 Adjust sample white cell count to within normal limits if it is raised.
- 2 Add 100 µl sample to FACS tube.
- 3 Wash $\times 3$ in warm (37°C) PBS to remove excess proteins from the sample.
- 4 Continue with surface staining as previously described.

Intracellular Staining

- 1 Carry out surface staining as described in steps 1–5 above, if required.
- 2 Wash $\times 1$ in warm (37°C) PBS.
- 3 Using Fix and Perm[®] Cell permeabilization reagents add 100 µl Reagent A (fixing reagent) and incubate for 15 min.
- 4 Wash $\times 1$ in warm (37°C) PBS, centrifuge for 5 min at 300–500 g.
- 5 Add 100 µl Reagent B (permeabilizing reagent) and appropriate volume of antibody conjugate.
- 6 Incubate 20–30 min in the dark

- 7 Add appropriate volume of ammonium chloride RBC lysing solution and vortex.
 - 8 Allow to lyse for 10 min.
 - 9 Analyse on flow cytometer.
- PBS; phosphate buffered saline, RBC; red blood cell solution.

The flow cytometer

There are three main components to the flow cytometer [8]:

1 The Fluidics System

Presentation of the sample to the laser.

2 The Optical System

Gathering information from the scattered light of the analysis.

3 The Computer/Electronic System

Conversion of optical to digital signals for display.

The fluidic system

The aim of the fluidics system is to present cells (or particles) in suspension to the laser interrogation point (the point at which cells pass through the laser light beam) one cell at a time. This is achieved by a process known as 'hydrodynamic focusing' (Figure 2.1). In the flow cell (flow chamber) the sample stream is injected into a faster moving stream of sheath fluid (usually phosphate buffered saline). Differences in the pressure, velocity and density of




Figure 2.1 Hydrodynamic focusing and interrogation point. The sample core is a narrow coaxial stream (stream within a stream) surrounded by a wider stream of sheath fluid. The shape of the flow cell helps minimize turbulence while ensuring the sample core is focused in the centre of the stream for presentation to the laser. Courtesy of Becton Dickinson.




Figure 2.2 Flow rate and sample pressure. Low flow rate=low sample pressure=narrow sample stream=cells pass beam in single file. High flow rate=high sample pressure=wider sample stream=more than one cell passes through the beam at a time. Courtesy of Becton Dickinson.

the two fluids prevent them from mixing. The flow cell is designed so that at the laser interrogation point the two streams are under pressure, focusing the sample stream in the centre of the sheath fluid, forcing the cells into single file before passing through the laser beam [3, 5, 6, 8].

Sample pressure is always greater than the sheath pressure. Altering the rate at which the cell suspension is injected into the centre of the sheath fluid will have a direct effect on the width of the sample stream and the number of cells passing through the interrogation point. The higher the sample pressure the wider the coaxial stream, resulting in more cells passing the interrogation point in a less than optimal position. By lowering the sample pressure this narrows the coaxial stream, resulting in cells passing the interrogation point in single file (Figure 2.2).

It is important that the correct flow rate is applied for the application being used. For immunophenotyping, measurements can be acquired quickly and therefore a high flow rate can be applied. DNA analysis, for example, requires a much higher resolution so a narrow sample core is necessary to ensure single cells pass through the laser beam at any given time; here a low flow rate should be applied.

The optical system

The optical system of the flow cytometer comprises excitation optics and collection optics. The excitation optics are




Figure 2.3 Example of the optical bench in the FACSCalibur flow cytometer. Courtesy of Becton Dickinson.

made up of the laser with focusing lenses and prisms, whilst the collection optics lenses, mirrors and filters all gather and direct the scattered light to specific optical detectors (Figure 2.3). The intercept point of laser light and cells must be constant so the laser is held in a fixed position.

Light scatter

As a cell passes through the interrogation point, light from the laser beam is scattered in forward and 90° angles. The amount of light scattered is dependent on the physical properties of the cell, such as, cell size, nuclear complexity and cytoplasmic granularity. These light scattering signals are gathered by specific detectors, converted to digital signals and finally displayed as dot plots for analysis.

Light diffracted at narrow angles to the laser beam is called forward scattered light (FSC) or forward angle light scatter (FALS). The amount of FSC is proportional to the surface area or size of the cell. The forward scattered light is collected by a detector placed in line with the laser beam on the opposite side of the sample stream. Some light will pass through the cell membrane and is refracted and reflected by cytoplasmic organelles or nucleus of the cell. This light is collected by a photodiode positioned at approximately 90° to the laser beam and is known as side scattered light (SSC). Side scattered light is proportional to the granularity or internal complexity of the cell (Figure 2.4).

Together, FSC and SSC signals provide information on the physical properties of the cells allowing differentiation of cells within a heterogeneous population, for example the differentiation of white blood cells (Figure 2.5).




Figure 2.4 Simple illustration of forward and side light scatter properties of a cell. Courtesy of Becton Dickinson.




Figure 2.5 Schematic diagram of differentiation of peripheral blood leucocytes according to forward and side scatter characteristics.

Fluorescence

The forward and side scatter light signals are emitted at a 488 nm wavelength and are of the same colour as the laser light [3]. These signals can therefore be determined without the need for a dedicated fluorescent probe.

To determine the specific biochemical properties of a cell, dyes that can bind directly to the cell or fluorochromes that are bound to ligands, for example monoclonal antibodies, are used. The dyes or fluorochromes are excited by light of a wavelength that is characteristic for

that molecule. It will absorb the light, gaining energy, resulting in the excitation of electrons within the molecule; on returning to its unexcited state this excess energy is released as photons of light resulting in fluorescence.

The wavelength range at which a fluorochrome absorbs light and becomes excited is known as its excitation (or absorption) wavelength. The wavelength range of the emitted light is termed its emission wavelength. The emitted wavelength range will be longer than that of the absorption wavelength range; this difference is referred

to as Stoke's Shift [5] (Figure 2.6). As laser light is of a fixed wavelength, it is essential that the fluorochromes or dyes to be used have excitation wavelengths compatible with the flow cytometer (Table 2.1).

If a fluorochrome or dye can be excited sufficiently by light of a specific wavelength and their emission wavelengths are sufficiently different from one another, more than one fluorescent compound may be used at one time. However, if the flow cytometer uses only a single

laser then the absorption spectrum of each fluorochrome would have to be similar.

In the flow cytometer the fluorescent signals are collected by photomultiplier tubes. To optimize these signals, optical filters specific to a wavelength range are placed in front of the photomultiplier, allowing only a narrow range of wavelength to reach the detector. These are as follows: bandpass (BP) filters which transmit light within a specified wavelength range (Figure 2.7)




Figure 2.6 Stoke's shift. Courtesy of Becton Dickinson.

Table 2.1 Maximum excitation and emission wavelengths for some of the common fluorochromes used in flow cytometry.

Fluorochrome	Abbreviation	Excitation max (nm)	Emission max (nm)
Cascade blue		380, 401	419
Cascade yellow		399	549
Pacific blue		410	455
Alexa 488*		495	519
Fluorescein isothiocyanate*	FITC	494	519
Phycoerythrin*	PE	496, 546	578
Texas red*	ECD	595	615
PE-cyanine 5*	PC5/PE-Cy5	496, 546	667
PE-cyanine 5.5*	PC5.5/PE-Cy5.5	495, 564	696
PE-cyanine 7*	PC7/PE-Cy7	495, 564	767
Peridinin-chlorophyll*	PerCP	482	678
PerCP-cyanine 5.5	PerCP-Cy5.5	482	678
Allophycocyanin*	APC	650	660
APC-cyanine 7	APC-Cy7	650	785

(*most commonly used).




Figure 2.7 Bandpass filters allowing only specific wavelengths of fluorescence to pass through. Courtesy of Becton Dickinson.

(a); shortpass (SP) filters (b) which transmit light with wavelengths equal to or shorter than specified; longpass (LP) filters (c) which transmit light with wavelengths equal to or longer than specified.

Fluorescence intensity

The brightness or fluorescence intensity of any captured event for a particular fluorochrome is recorded by the cytometer for that channel. When many events have been captured it is possible to derive a mean fluorescence value; this is known as the mean fluorescence intensity (MFI) and is a very important characteristic that should be assessed in routine diagnostic practice (Figure 2.8a). It relates to not only the presence of the relevant antigen, but also the strength of expression or integrity of that antigen in a given cell population. It can carry great significance when used in the differentiation of neoplastic from reactive and normal cell populations. Fluorescence intensity can also be used to identify dual populations and allow subsequent directed gating strategies (Figure 2.8b). Some cell populations can show a spectrum of expression of a given antigen, for example CD13 expression in acute myeloid leukaemia, so care has to be used when using MFI data without paying attention to the plot (Figure 2.8c). These patterns of expression can be important in diagnosis.

It is clearly important to maintain consistency in fluorescence intensity data, both on a single cytometer over time and between different cytometers in the same laboratory. The means of achieving this are explained in the calibration section below.

Spectral overlap

Although a detector is designed to collect fluorescence from a specific wavelength, the emission spectra for a given fluorochrome can cover a range of wavelengths, allowing fluorescence spill over to a detector designed for a different fluorochrome. This is referred to as spectral overlap (Figure 2.9). For accurate analysis of data, the spectral overlap between fluorochromes must be corrected. This correction is done by compensation (Figure 2.10). In simple terms, compensation is carried out by correcting for inappropriate signals generated by the fluorochrome responsible for the overlap. With the use of compensation controls, this can be corrected manually and visually set, so minimizing interference from this phenomenon. However, when using multiple




Figure 2.8 (a) Deriving a CD20⁺ MFI value for a B-cell population in blood. (b) Differences in CD20 MFI values for two different B-cell populations in blood can assist in diagnosis. (c) In addition to MFI, the spectrum of fluorescence intensity for a given antigen is important. Here, although the MFI is the same for the two myeloid populations, the variation in intensity (heterogenous versus homogenous expression) is different and is valuable in diagnosis.